nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR2B—Sorafenib—liver cancer	0.501	0.606	CbGbCtD
Methysergide—HTR2C—Sorafenib—liver cancer	0.326	0.394	CbGbCtD
Methysergide—Gastrointestinal symptom NOS—Sorafenib—liver cancer	0.00888	0.0514	CcSEcCtD
Methysergide—Gravitational oedema—Epirubicin—liver cancer	0.0079	0.0457	CcSEcCtD
Methysergide—Gravitational oedema—Doxorubicin—liver cancer	0.00731	0.0423	CcSEcCtD
Methysergide—Leg edema—Epirubicin—liver cancer	0.00716	0.0415	CcSEcCtD
Methysergide—Pleural effusion—Sorafenib—liver cancer	0.00682	0.0395	CcSEcCtD
Methysergide—Leg edema—Doxorubicin—liver cancer	0.00663	0.0384	CcSEcCtD
Methysergide—Pain in extremity—Sorafenib—liver cancer	0.00379	0.0219	CcSEcCtD
Methysergide—Neutropenia—Sorafenib—liver cancer	0.00306	0.0177	CcSEcCtD
Methysergide—Weight decreased—Sorafenib—liver cancer	0.00296	0.0171	CcSEcCtD
Methysergide—Pleural effusion—Epirubicin—liver cancer	0.00252	0.0146	CcSEcCtD
Methysergide—Hyperaesthesia—Epirubicin—liver cancer	0.00246	0.0142	CcSEcCtD
Methysergide—Flushing—Sorafenib—liver cancer	0.00243	0.0141	CcSEcCtD
Methysergide—Pleural effusion—Doxorubicin—liver cancer	0.00233	0.0135	CcSEcCtD
Methysergide—Alopecia—Sorafenib—liver cancer	0.00232	0.0134	CcSEcCtD
Methysergide—Hyperaesthesia—Doxorubicin—liver cancer	0.00227	0.0132	CcSEcCtD
Methysergide—Oliguria—Epirubicin—liver cancer	0.00209	0.0121	CcSEcCtD
Methysergide—Arthralgia—Sorafenib—liver cancer	0.00194	0.0112	CcSEcCtD
Methysergide—Myalgia—Sorafenib—liver cancer	0.00194	0.0112	CcSEcCtD
Methysergide—Oliguria—Doxorubicin—liver cancer	0.00194	0.0112	CcSEcCtD
Methysergide—Thrombocytopenia—Sorafenib—liver cancer	0.00182	0.0106	CcSEcCtD
Methysergide—Blood urea increased—Epirubicin—liver cancer	0.00182	0.0105	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Sorafenib—liver cancer	0.0017	0.00982	CcSEcCtD
Methysergide—Blood urea increased—Doxorubicin—liver cancer	0.00168	0.00975	CcSEcCtD
Methysergide—Dyspnoea—Sorafenib—liver cancer	0.00166	0.00961	CcSEcCtD
Methysergide—Dyspepsia—Sorafenib—liver cancer	0.00164	0.00949	CcSEcCtD
Methysergide—Thrombophlebitis—Epirubicin—liver cancer	0.00162	0.00936	CcSEcCtD
Methysergide—Gastrointestinal disorder—Sorafenib—liver cancer	0.00161	0.00931	CcSEcCtD
Methysergide—Fatigue—Sorafenib—liver cancer	0.00161	0.00929	CcSEcCtD
Methysergide—Pain—Sorafenib—liver cancer	0.00159	0.00922	CcSEcCtD
Methysergide—Constipation—Sorafenib—liver cancer	0.00159	0.00922	CcSEcCtD
Methysergide—Gastrointestinal pain—Sorafenib—liver cancer	0.00152	0.00881	CcSEcCtD
Methysergide—Thrombophlebitis—Doxorubicin—liver cancer	0.0015	0.00866	CcSEcCtD
Methysergide—Body temperature increased—Sorafenib—liver cancer	0.00147	0.00852	CcSEcCtD
Methysergide—Abdominal pain—Sorafenib—liver cancer	0.00147	0.00852	CcSEcCtD
Methysergide—Pain in extremity—Epirubicin—liver cancer	0.0014	0.00811	CcSEcCtD
Methysergide—Asthenia—Sorafenib—liver cancer	0.00134	0.00773	CcSEcCtD
Methysergide—Ataxia—Epirubicin—liver cancer	0.00132	0.00762	CcSEcCtD
Methysergide—Pain in extremity—Doxorubicin—liver cancer	0.0013	0.0075	CcSEcCtD
Methysergide—Orthostatic hypotension—Epirubicin—liver cancer	0.00128	0.0074	CcSEcCtD
Methysergide—Diarrhoea—Sorafenib—liver cancer	0.00127	0.00738	CcSEcCtD
Methysergide—Dizziness—Sorafenib—liver cancer	0.00123	0.00713	CcSEcCtD
Methysergide—Ataxia—Doxorubicin—liver cancer	0.00122	0.00705	CcSEcCtD
Methysergide—Eosinophilia—Epirubicin—liver cancer	0.0012	0.00694	CcSEcCtD
Methysergide—Vomiting—Sorafenib—liver cancer	0.00118	0.00685	CcSEcCtD
Methysergide—Orthostatic hypotension—Doxorubicin—liver cancer	0.00118	0.00685	CcSEcCtD
Methysergide—Rash—Sorafenib—liver cancer	0.00117	0.0068	CcSEcCtD
Methysergide—Dermatitis—Sorafenib—liver cancer	0.00117	0.00679	CcSEcCtD
Methysergide—Dysuria—Epirubicin—liver cancer	0.00113	0.00655	CcSEcCtD
Methysergide—Neutropenia—Epirubicin—liver cancer	0.00113	0.00655	CcSEcCtD
Methysergide—Eosinophilia—Doxorubicin—liver cancer	0.00111	0.00642	CcSEcCtD
Methysergide—Nausea—Sorafenib—liver cancer	0.00111	0.0064	CcSEcCtD
Methysergide—Weight increased—Epirubicin—liver cancer	0.0011	0.00638	CcSEcCtD
Methysergide—Weight decreased—Epirubicin—liver cancer	0.00109	0.00634	CcSEcCtD
Methysergide—Drowsiness—Epirubicin—liver cancer	0.00108	0.00625	CcSEcCtD
Methysergide—Dysuria—Doxorubicin—liver cancer	0.00105	0.00606	CcSEcCtD
Methysergide—Neutropenia—Doxorubicin—liver cancer	0.00105	0.00606	CcSEcCtD
Methysergide—Weight increased—Doxorubicin—liver cancer	0.00102	0.0059	CcSEcCtD
Methysergide—Weight decreased—Doxorubicin—liver cancer	0.00101	0.00586	CcSEcCtD
Methysergide—Drowsiness—Doxorubicin—liver cancer	0.000998	0.00578	CcSEcCtD
Methysergide—Oedema peripheral—Epirubicin—liver cancer	0.000954	0.00552	CcSEcCtD
Methysergide—Flushing—Epirubicin—liver cancer	0.000899	0.0052	CcSEcCtD
Methysergide—Oedema peripheral—Doxorubicin—liver cancer	0.000883	0.00511	CcSEcCtD
Methysergide—Alopecia—Epirubicin—liver cancer	0.000856	0.00495	CcSEcCtD
Methysergide—Flushing—Doxorubicin—liver cancer	0.000832	0.00482	CcSEcCtD
Methysergide—Back pain—Epirubicin—liver cancer	0.000816	0.00472	CcSEcCtD
Methysergide—Alopecia—Doxorubicin—liver cancer	0.000792	0.00458	CcSEcCtD
Methysergide—Ill-defined disorder—Epirubicin—liver cancer	0.000782	0.00453	CcSEcCtD
Methysergide—Malaise—Epirubicin—liver cancer	0.00076	0.0044	CcSEcCtD
Methysergide—Back pain—Doxorubicin—liver cancer	0.000755	0.00437	CcSEcCtD
Methysergide—Convulsion—Epirubicin—liver cancer	0.000731	0.00423	CcSEcCtD
Methysergide—Ill-defined disorder—Doxorubicin—liver cancer	0.000724	0.00419	CcSEcCtD
Methysergide—Myalgia—Epirubicin—liver cancer	0.000718	0.00416	CcSEcCtD
Methysergide—Arthralgia—Epirubicin—liver cancer	0.000718	0.00416	CcSEcCtD
Methysergide—Chest pain—Epirubicin—liver cancer	0.000718	0.00416	CcSEcCtD
Methysergide—Discomfort—Epirubicin—liver cancer	0.000709	0.00411	CcSEcCtD
Methysergide—Malaise—Doxorubicin—liver cancer	0.000704	0.00407	CcSEcCtD
Methysergide—Oedema—Epirubicin—liver cancer	0.000688	0.00398	CcSEcCtD
Methysergide—Convulsion—Doxorubicin—liver cancer	0.000676	0.00391	CcSEcCtD
Methysergide—Thrombocytopenia—Epirubicin—liver cancer	0.000674	0.0039	CcSEcCtD
Methysergide—Tachycardia—Epirubicin—liver cancer	0.000672	0.00389	CcSEcCtD
Methysergide—Chest pain—Doxorubicin—liver cancer	0.000664	0.00385	CcSEcCtD
Methysergide—Myalgia—Doxorubicin—liver cancer	0.000664	0.00385	CcSEcCtD
Methysergide—Arthralgia—Doxorubicin—liver cancer	0.000664	0.00385	CcSEcCtD
Methysergide—Discomfort—Doxorubicin—liver cancer	0.000656	0.0038	CcSEcCtD
Methysergide—Oedema—Doxorubicin—liver cancer	0.000637	0.00369	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000627	0.00363	CcSEcCtD
Methysergide—Thrombocytopenia—Doxorubicin—liver cancer	0.000623	0.00361	CcSEcCtD
Methysergide—Insomnia—Epirubicin—liver cancer	0.000622	0.0036	CcSEcCtD
Methysergide—Tachycardia—Doxorubicin—liver cancer	0.000621	0.0036	CcSEcCtD
Methysergide—Paraesthesia—Epirubicin—liver cancer	0.000618	0.00358	CcSEcCtD
Methysergide—Dyspnoea—Epirubicin—liver cancer	0.000613	0.00355	CcSEcCtD
Methysergide—Somnolence—Epirubicin—liver cancer	0.000612	0.00354	CcSEcCtD
Methysergide—Dyspepsia—Epirubicin—liver cancer	0.000606	0.00351	CcSEcCtD
Methysergide—Gastrointestinal disorder—Epirubicin—liver cancer	0.000594	0.00344	CcSEcCtD
Methysergide—Fatigue—Epirubicin—liver cancer	0.000593	0.00343	CcSEcCtD
Methysergide—Constipation—Epirubicin—liver cancer	0.000588	0.00341	CcSEcCtD
Methysergide—Pain—Epirubicin—liver cancer	0.000588	0.00341	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00058	0.00336	CcSEcCtD
Methysergide—Insomnia—Doxorubicin—liver cancer	0.000576	0.00333	CcSEcCtD
Methysergide—Paraesthesia—Doxorubicin—liver cancer	0.000572	0.00331	CcSEcCtD
Methysergide—Dyspnoea—Doxorubicin—liver cancer	0.000568	0.00329	CcSEcCtD
Methysergide—Feeling abnormal—Epirubicin—liver cancer	0.000567	0.00328	CcSEcCtD
Methysergide—Somnolence—Doxorubicin—liver cancer	0.000566	0.00328	CcSEcCtD
Methysergide—Gastrointestinal pain—Epirubicin—liver cancer	0.000563	0.00326	CcSEcCtD
Methysergide—Dyspepsia—Doxorubicin—liver cancer	0.00056	0.00324	CcSEcCtD
Methysergide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00055	0.00318	CcSEcCtD
Methysergide—Fatigue—Doxorubicin—liver cancer	0.000549	0.00318	CcSEcCtD
Methysergide—Pain—Doxorubicin—liver cancer	0.000544	0.00315	CcSEcCtD
Methysergide—Constipation—Doxorubicin—liver cancer	0.000544	0.00315	CcSEcCtD
Methysergide—Body temperature increased—Epirubicin—liver cancer	0.000544	0.00315	CcSEcCtD
Methysergide—Abdominal pain—Epirubicin—liver cancer	0.000544	0.00315	CcSEcCtD
Methysergide—Feeling abnormal—Doxorubicin—liver cancer	0.000525	0.00304	CcSEcCtD
Methysergide—Gastrointestinal pain—Doxorubicin—liver cancer	0.000521	0.00301	CcSEcCtD
Methysergide—Abdominal pain—Doxorubicin—liver cancer	0.000503	0.00291	CcSEcCtD
Methysergide—Body temperature increased—Doxorubicin—liver cancer	0.000503	0.00291	CcSEcCtD
Methysergide—Asthenia—Epirubicin—liver cancer	0.000494	0.00286	CcSEcCtD
Methysergide—Diarrhoea—Epirubicin—liver cancer	0.000471	0.00273	CcSEcCtD
Methysergide—Asthenia—Doxorubicin—liver cancer	0.000457	0.00264	CcSEcCtD
Methysergide—Dizziness—Epirubicin—liver cancer	0.000455	0.00263	CcSEcCtD
Methysergide—Vomiting—Epirubicin—liver cancer	0.000438	0.00253	CcSEcCtD
Methysergide—Diarrhoea—Doxorubicin—liver cancer	0.000436	0.00252	CcSEcCtD
Methysergide—Rash—Epirubicin—liver cancer	0.000434	0.00251	CcSEcCtD
Methysergide—Dermatitis—Epirubicin—liver cancer	0.000433	0.00251	CcSEcCtD
Methysergide—Dizziness—Doxorubicin—liver cancer	0.000421	0.00244	CcSEcCtD
Methysergide—Nausea—Epirubicin—liver cancer	0.000409	0.00237	CcSEcCtD
Methysergide—Vomiting—Doxorubicin—liver cancer	0.000405	0.00234	CcSEcCtD
Methysergide—Rash—Doxorubicin—liver cancer	0.000401	0.00232	CcSEcCtD
Methysergide—Dermatitis—Doxorubicin—liver cancer	0.000401	0.00232	CcSEcCtD
Methysergide—Nausea—Doxorubicin—liver cancer	0.000378	0.00219	CcSEcCtD
